Patient Support Services Contact Us
Image: Coherus Investors

Overview

Investors

A fully integrated biopharmaceutical company with a robust pipeline across multiple therapeutic areas.

Coherus is a commercial stage biopharmaceutical company with the mission to increase patient access to cost-effective medicines that can have a major impact on their lives and to deliver significant savings to the health care system.

In January 2021, Coherus in-licensed Junshi Biosciences’ toripalimab, an anti-PD-1 antibody, which will be a cornerstone of Coherus’ strategy to build a leading immuno-oncology franchise in the United States and Canada funded with cash generated by its commercial biosimilar business. Coherus markets UDENYCA® (pegfilgrastim-cbqv) in the United States and through 2023 expects to launch biosimilars of Humira®, Avastin® and Lucentis®, if approved.

Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.

News
09/19/22
- CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis ®  (ranibizumab injection) for all indications, with 12 months of interchangeability exclusivity - - Interchangeability designation and clinical equivalence to Lucentis provides confidence that existing Lucentis
09/12/22
REDWOOD CITY, Calif. , Sept. 12, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24 th Annual Global Investment Conference on Wednesday, September 14 at 10:00 am ET .
08/29/22
REDWOOD CITY, Calif. , Aug. 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 24, 2022 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 234,000 shares
08/04/22
– Commercial launch of CIMERLI ™ planned for early October 2022 – – PDUFA date for toripalimab BLA is December 23, 2022 – – Commercial preparation underway for planned July 2023 launch of YUSIMRY ™ – – UDENYCA® delivers 2 nd quarter 2022 net sales of $60.1 million – – Conference call today at 5
Events & Presentations